[Skip to Navigation]
September 15, 2021

An Expanded Heart Failure Indication for Sacubitril/Valsartan: Evolving the Evidence Bar

Author Affiliations
  • 1Northwestern University Feinberg School of Medicine, Chicago, Illinois
  • 2Deputy Editor, JAMA Cardiology
JAMA Cardiol. 2021;6(12):1357-1358. doi:10.1001/jamacardio.2021.3658

The new Universal Definition for Heart Failure partitions heart failure phenotypes according to ejection fraction criteria.1 For those with signs and symptoms of heart failure and a corresponding left ventricular ejection fraction (LVEF) less than 40%, the designation is once again heart failure with reduced ejection fraction (HFrEF). Similarly, for those with signs and symptoms of heart failure and corresponding LVEF of 41% to 49% and greater than 50%, the designations are heart failure with midrange ejection fraction and heart failure with preserved ejection fraction (HFpEF), respectively.1

Add or change institution